Assessing Daily Life Physical Activity by Actigraphy in Pulmonary Arterial Hypertension: Insights From the Randomized Controlled Study With Selexipag (TRACE).

"Financial/Nonfinancial Disclosures The authors have reported to CHEST the following: L. S. H. has served as a steering committee member for Janssen Pharmaceutical Companies of Johnson & Johnson, Gossamer Bio, and Lung Biotechnology; has received research grants from Janssen Pharmaceutical Companies of Johnson & Johnson; has received speakers fees from Bayer PLC, Janssen Pharmaceutical Companies of Johnson & Johnson, and Merck; has received support for attending meetings and/or travel from Janssen Pharmaceutical Companies of Johnson & Johnson; has been a member of an advisory board for Acceleron, Janssen Pharmaceutical Companies of Johnson & Johnson, and Merck; and is a shareholder in iOWNA and Circular. S. R. has served as a steering committee member for Janssen Pharmaceutical Companies of Johnson & Johnson; has received research grants from AstraZeneca, Bayer, Janssen Pharmaceutical Companies of Johnson & Johnson, and Novartis; has received consulting fees from and been an advisory board member for Abbott, Acceleron, Bayer, BMS, Gilead, Janssen Pharmaceutical Companies of Johnson & Johnson, MSD, Novartis, Pfizer, United Therapeutics, and Vifor; has received honoraria from Abbott, Bayer, BMS, Ferrer, Janssen Pharmaceutical Companies of Johnson & Johnson, MSD, Novartis, Pfizer, UT, and Vifor; and has been a past chair for the European Society of Cardiology, member of the Pulmonary Circulation and Right Ventricular Function working group, and is currently a 2022 task force chair. R. P. F. has served as a steering committee member for Janssen Pharmaceutical Companies of Johnson & Johnson; has received grants or contracts from the National Heart, Lung, and Blood Institute; has received consulting fees from Janssen Pharmaceutical Companies of Johnson & Johnson, Liquidia, ShouTi, Altavant, Gossamer Bio, and Bayer; has received honoraria from United Therapeutics, France Foundation, and Janssen Pharmaceutical Companies of Johnson & Johnson; and has participated on a data safety monitoring board/advisory board for Janssen Pharmaceutical Companies of Johnson & Johnson and Liquidia. A. R. H. has served as a steering committee member for Janssen Pharmaceutical Companies of Johnson & Johnson; has received grants from the National Institutes of Health, the Cardiovascular Medical Research and Education Fund, and Imara; has received consultancy fees from Acceleron, Bayer, Gossamer Bio, Janssen Pharmaceutical Companies of Johnson & Johnson, and United Therapeutics; and holds stock/stock options in Tenax Therapeutics. T. P. and S.-F. H. S. are employees of Actelion Pharmaceuticals Ltd. H. S. has served as a steering committee member for Janssen Pharmaceutical Companies of Johnson & Johnson; has received consulting fees from Janssen Pharmaceutical Companies of Johnson & Johnson; and is a stockholder in Bellerophon Therapeutics, Inc. M. H. has served as a steering committee member for Janssen Pharmaceutical Companies of Johnson & Johnson, Acceleron, and Merck; has received research funding from Janssen Pharmaceutical Company of Johnson & Johnson; has received grants or contracts from Acceleron, Janssen Pharmaceutical Companies of Johnson & Johnson, and Merck; has received consulting fees from Acceleron, Janssen Pharmaceutical Companies of Johnson & Johnson, and Merck; has received speaker fees from AOP Orphan Pharmaceuticals, Janssen Pharmaceutical Companies of Johnson & Johnson, and Merck; and has participated on an advisory board for Acceleron, Janssen Pharmaceutical Companies of Johnson & Johnson, Merck, and United Therapeutics. I. R. P. has served as a steering committee member for Acceleron, Janssen Pharmaceutical Companies of Johnson & Johnson, and United Therapeutics; has served as an adjudication committee member for Pfizer; has received grants or contracts from Janssen Pharmaceutical Companies of Johnson & Johnson, PhaseBio, Tenax, and United Therapeutics; has received consultancy fees from Altavant; has received payment for lectures from Janssen Pharmaceutical Companies of Johnson & Johnson; and has received payment for expert testimony from Bayer."

"Funding/Support This study was funded by 10.13039/100005646Actelion Pharmaceuticals Ltd, a Janssen Pharmaceutical Company of 10.13039/100004331Johnson & Johnson."

"Clinical Trial Registration ClinicalTrials.gov; No.: NCT03078907; URL: www.clinicaltrials.gov"